Listen to article
6:19Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 29 October 2026
Read article
Published on 28 October 2026
Read article
Published on 27 October 2026
Read article
Published on 26 October 2026
Read article
Published on 24 October 2026
Read article
When a giant like Merck splashes out over nine billion dollars on a company, you tend to sit up and take notice. Their recent acquisition of Cidara Therapeutics wasn't just another Tuesday transaction. To me, it felt like the starting pistol for a frantic, high-stakes shopping spree, and it seems Big Pharma has arrived with a very long list and a very fat wallet.
Let’s be clear, this isn't about choice. The pharmaceutical behemoths are being driven by sheer, unadulterated panic. They are staring into a financial black hole known as the "patent cliff". Imagine your most profitable product, the one that keeps the lights on, suddenly becoming available for a tenth of the price from a competitor. Now imagine that happening to dozens of your products over the next few years. That’s the reality they face.
Developing a new blockbuster drug from scratch is a monstrously expensive and time consuming affair, often taking more than a decade with no guarantee of success. So, what’s the alternative when your revenue streams are about to dry up? You go shopping. It’s far quicker, and in some ways less risky, to simply buy a smaller company that has already done the hard yards and has a promising drug candidate nearing the finish line.
Of course, they aren't just throwing money at any lab with a few petri dishes. The most sought after targets are the ones that have already navigated the treacherous early stages of clinical trials. We’re talking about companies with drugs in Phase II or Phase III, where the initial risks have been ironed out. They are often specialists in lucrative fields like oncology or rare genetic diseases, areas where a single successful treatment can be worth billions.
You see companies like ACRIVON THERAPEUTICS, with its focus on precision cancer treatments, or Bridgebio Pharma, which tackles rare genetic conditions, and you can almost see the logic forming in a Big Pharma boardroom. These aren't wild punts. They are calculated acquisitions of de-risked, high potential assets. The challenge for investors, naturally, is figuring out how to spot these potential golden geese. Some are exploring curated lists of firms that fit this specific profile, such as the Biotech Buyout Candidates (Post-Merck Acquisition) basket, to get a sense of the landscape.
Now, before you get too carried away, let’s pour a little cold water on things. Investing in biotech is not for the faint of heart. It is a brutal, volatile world where fortunes can be made or lost on the back of a single clinical trial result. For every company that gets bought out for a handsome premium, there are dozens that quietly fade away after a promising treatment fails to deliver.
The path to approval is littered with regulatory hurdles and unexpected setbacks. A company can look like the most attractive target in the world one day, and a complete dud the next. This is a high stakes game, and anyone telling you otherwise is probably trying to sell you something. The potential rewards are significant, but you must go in with your eyes wide open to the very real risks. This is not a place for your retirement fund, unless you enjoy a bit of a flutter.
View the full Basket:Biotech Buyout Candidates (Post-Merck Acquisition)
View the full Basket:Biotech Buyout Candidates (Post-Merck Acquisition)
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 29 October 2026
Read article
Published on 28 October 2026
Read article
Published on 27 October 2026
Read article
Published on 26 October 2026
Read article
Published on 24 October 2026
Read article
